Joe Mendez, MD
Neurological Surgery · Salt Lake City, UTNPI 1578819827
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (53.4%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 4 manufacturers reported payments, led by Servier Pharmaceuticals LLC at 45.3% of the total.
Across 17 payments — averaging $992.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Servier Pharmaceuticals LLC$8K
- BTG International Inc.$7K
- Jazz Pharmaceuticals Inc.$2K
- Agios Pharmaceuticals, Inc.$185
Across 370 payments — averaging $4510.09 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Servier Bioinnovation$1.2M
- Servier Pharmaceuticals LLC$176K
- Agios Pharmaceuticals, Inc.$117K
- Jazz Pharmaceuticals Inc.$92K
- Incyte Corporation$50K
- AbbVie$16K
- plus $7K from 1 others
What the payments were for
- Consulting fees$5,93435%
- Speaking & faculty fees$9,01853%
- Travel & lodging$1,2307%
- Food & beverage$6894%
- Education$00%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Servier Pharmaceuticals LLC | 6 | $7,642 |
| BTG International Inc. | 8 | $7,095 |
| Jazz Pharmaceuticals Inc. | 2 | $1,950 |
| Agios Pharmaceuticals, Inc. | 1 | $185 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$16,872 in reported general payments places this provider in the 80th percentile of 75 neurological surgery providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 11 | $200,831 |
| GleostineLomustine | 20 | $25,449 |
| MatulaneProcarbazine Hcl | 19 | $22,586 |
| EliquisApixaban | 13 | $14,771 |
| Ondansetron Hcl | 35 | $8,402 |
| Levetiracetam | 41 | $1,736 |
| Dexamethasone | 13 | $313 |
| Prochlorperazine Maleate | 14 | $208 |
| Quetiapine Fumarate | 12 | $111 |
| Escitalopram Oxalate | 13 | $40 |
Paid to pharmacies, not to this prescriber.
Other neurological surgery in Salt Lake City
- Mark MahanSalt Lake City$698K
- Ramesh GrandhiSalt Lake City$586K
- Kenneth YonemuraSalt Lake City$117K
- Andrew DaileySalt Lake City$74K
- Craig KilburgSalt Lake City$66K
- Ronald ApfelbaumSalt Lake City$56K
- Guilherme Santos PiedadeSalt Lake City$51K
- Karol BudohoskiSalt Lake City$30K
- Randy JensenSalt Lake City$22K
- Ilyas EliSalt Lake City$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.